Goal:

To educate pharmacists about MS pathophysiology and the new American Academy of Neurology recommendations for the use of disease-modifying therapies (DMTs) in adults.

Educational Objectives:

Upon completion of this activity, participants should be better able to:

1. DESCRIBE the pathophysiological mechanisms that contribute to multiple sclerosis (MS)
2. EVALUATE the safety and efficacy of available disease-modifying therapies
3. EMPLOY care coordination strategies that emphasize multidisciplinary collaboration and advocacy for individuals with MS
4. DEFINE the pharmacist’s role in providing drug management and administrative support to people receiving MS therapy and their providers